Abstract
The objective of this study was to evaluate the initial response to treatment and the long-term outcome of patients with papillary thyroid cancer (PTC), according to the modified 2014 risk of recurrence classification of the American Thyroid Association and the presence or absence of insulin resistance (IR). We retrospectively reviewed our database of 636 records and selected 171 patients in whom we had previously validated the ATA risk of recurrence (RR) classification. From these patients, 38 non-diabetic subjects were included for analysis according to the following criteria: age older than 18 years, classic papillary thyroid carcinoma, stable body mass index 5 years previous to PTC diagnosis and during the entire time of follow-up, low and intermediate RR, follow-up after initial treatment at least for 3 years, and absence of any drug treatment for the metabolic syndrome. The IR was evaluated through the homeostasis model assessment (HOMA) index. When equal or higher than 2.5, patients were considered as harboring IR. The initial response to treatment was classified as remission or persistent disease (biochemical and/or structural). The clinical status at final follow-up was defined as no evidence of disease, biochemical persistent disease, structural persistent disease, or recurrence (biochemical or structural disease identified after a period of no evidence of disease). RR was as follows: low: n = 15, intermediate: n = 23. The median follow-up of this patient cohort was 5.5 years (range 3–22 years). We found no statistically significant differences when the response to initial treatment was considered in low-risk patients with or without IR. However, remission was more frequently found in those patients without IR when the intermediate RR was considered (36 vs. 11 %, p = 0.01). When considering the status at final follow-up, we found more frequency of structural persistent disease in both, low and intermediate RR patients with IR (10 vs. 0 %, p = 0.02 and 45 vs.7 %, p = 0.01, respectively). In this series of patients with PTC, the state of IR was associated with increased frequency of structural persistent disease at final follow-up. The IR could have a deleterious effect on the outcome of patients with PTC.
Similar content being viewed by others
References
A.G. Renehan, M. Tyson, M. Egger, R.F. Heller, M. Zwahlen, Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371, 569–578 (2008)
K. Esposito, A. Capuano, D. Giugliano, Metabolic syndrome and cancer: holistic or reductionist? Endocrine 45, 362–364 (2014)
K. Esposito, P. Chiodini, A. Capuano, G. Bellastella, M.I. Maiorino, C. Rafaniello, D.B. Panagiotakos, D. Giugliano, Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine 44, 634–647 (2013)
L.G. Morris, D. Myssiorek, Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. Am. J. Surg. 200, 454–461 (2010)
L. Davies, H. Welch, Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295, 2164–2167 (2006)
A.Y. Chen, A. Jemal, E.M. Ward, Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer 115, 3801–3807 (2009)
L. Enewold, K. Zhu, E. Ron, A.J. Marrogi, A. Stojadinovic, G.E. Peoples, S.S. Devesa, Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol. Biomark. Prev. 18, 784–791 (2009)
G. Danaei, M.M. Finucane, J.K. Lin, G.M. Singh, C.J. Paciorek, M.J. Cowan, F. Farzadfar, G.A. Stevens, S.S. Lim, L.M. Riley, M. Ezzati, Global burden of metabolic risk factors of chronic diseases collaborating group (blood pressure). National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet 377, 568–577 (2011)
T. Pappa, M. Alevizaki, Obesity and thyroid cancer: a clinical update. Thyroid 24, 190–199 (2014)
J. Rezzónico, M. Rezzónico, E. Pusiol, F. Pitoia, H. Niepomniszcze, Introducing the thyroid gland as another victim of the insulin resistance syndrome. Thyroid 18, 461–464 (2008)
S. Ayturk, A. Gursoy, A. Kut, C. Anil, A. Nar, N.B. Tutuncu, Metabolic syndrome and its components are associated with increased thyroid volume and nodule prevalence in a mild to moderate iodine deficient area. Eur. J. Endocrinol. 161, 599–605 (2009)
J. Rezzónico, M. Rezzónico, E. Pusiol, F. Pitoia, H. Niepomiszcze, Increase prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metab. Syndr. Relat. Disord. 7, 375–380 (2009)
F. Balkan, E.D. Onal, U. Alper, D. Tuzun, D. Ozdemir, S.S. Inancli, R. Ersoy, B. Cakir, Is there any association between insulin resistance and thyroid cancer?: a case control study. Endocrine 45, 55–60 (2014)
A. Gursoy, Rising thyroid cancer incidence in the world might be related to insulin resistance. Med. Hypotheses 74, 35–36 (2009)
M.T. Goodman, L.N. Kolonel, L.R. Wilkens, The association of body size, reproductive factors and thyroid cancer. Br. J. Cancer 66, 1180–1194 (1992)
C.M. Kitahara, E.A. Platz, L.E. Freeman, A.W. Hsing, M.S. Linet, Y. Park, C. Schairer, A. Schatzkin, J.M. Shikany, A. Berrington de González, Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiol. Biomarkers Prev. 20, 464–472 (2011)
Z.G. Zhao, X.G. Guo, C.X. Ba, W. Wang, Y.Y. Yang, J. Wang, H.Y. Cao, Overweight, obesity and thyroid cancer risk: a meta-analysis of cohort studies. J. Int. Med. Res. 40, 2041–2050 (2012)
H.J. Kim, N.K. Kim, J.H. Choi, S.Y. Sohn, S.W. Kim, S.M. Jin, H.W. Jang, S. Suh, Y.K. Min, J.H. Chung, S.W. Kim, Associations between body mass index and clinico-pathological characteristics of papillary thyroid cancer. Clin. Endocrinol. 78, 134–140 (2013)
A. Harari, B. End, S. Nishimoto, P.H. Ituarte, M.W. Yeh, Risk of advanced papillary thyroid cancer in obese patients. Arch. Surg. 147, 805–811 (2012)
J.E. Paes, K. Hua, R. Nagy, R.T. Kloos, D. Jarjoura, M.D. Ringel, The relationship between body mass index and thyroid cancer pathology features and outcomes: a clinicopathological cohort study. J. Clin. Endocrinol. Metab. 95, 4244–4250 (2010)
F. Pitoia, F. Bueno, C. Urciuoli, E. Abelleira, G. Cross, R.M. Tuttle, Outcomes of patients with differentiated thyroid cancer risk stratified according to the American Thyroid Association and Latin American Thyroid Society risk of recurrence classification systems. Thyroid 23, 1401–1407 (2013)
D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009)
G.W. Randolph, Q.Y. Duh, K.S. Heller, V.A. LiVolsi, S.J. Mandel, D.L. Steward, R.P. Tufano, R.M. Tuttle, American Thyroid Association Surgical Affairs Committee´s taskforce on thyroid cancer nodal surgery. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 22, 1144–1152 (2012)
Ito, A. Miyauchi, M. Kihara, K. Kobayashi, A. Miya. Prognostic values of clinical lymph node metastasis and macroscopic extrathyroid extension in papillary thyroid carcinoma. Endocr. J. 2014; [Epub ahead of print]
F. Pitoia, L. Ward, N. Wohllk, C. Friguglietti, E. Tomimori, A. Gauna, R. Camargo, M. Vaisman, R. Harach, F. Munizaga, S. Corigliano, E. Pretell, H. Niepomnizcze, Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq. Bras. Endocrinol. Metabol. 53, 884–887 (2009)
R.M. Tuttle, H. Tala, J. Shah, R. Leboeuf, R. Ghossein, M. Gonen, M. Brokhin, G. Omry, J.A. Fagin, A. Shaha, Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20, 1341–1349 (2010)
F. Vaisman, A. Shaha, S. Fish, R.M. Tuttle, Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin. Endocrinol. 75, 112–119 (2011)
M.G. Castagna, F. Maino, C. Cipri, V. Belardini, A. Theodoropoulou, G. Cevenini, F. Pacini, Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur. J. Endocrinol. 165, 441–446 (2011)
S. Bardet, E. Malville, J.P. Rame, E. Babin, G. Samama, G.D. De Raucourt, J.J. Michels, Y. Reznik, M. Henry-Amar, Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. Eur. J. Endocrinol. 158, 551–560 (2008)
I.M. Cranshaw, B. Carnaille, Micrometastases in thyroid cancer. An important finding? Surg. Oncol. 17, 253–258 (2008)
S. Leboulleux, C. Rubino, E. Baudin, B. Caillou, D.M. Hartl, J.M. Bidart, J.P. Travagli, M. Schlumberger, Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J. Clin. Endocrinol. Metab. 90, 5723–5729 (2005)
C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J.P. Travagli, B. Caillou, M. Ricard, J.D. Lumbroso, F. De Vathaire, M. Schlumberger, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radiodine therapy. J. Clin. Endocrinol. Metab. 91, 2892–2899 (2006)
R.H. Eckel, S.M. Grundy, P.Z. Zimmet, The metabolic syndrome. Lancet 365, 1415–1428 (2005)
Z.T. Bloomgarden, Insulin resistance concepts. Diabetes Care 30, 1320–1326 (2007)
V. Vella, L. Sciacca, G. Pandini, R. Mineo, S. Squatrito, R. Vigneri, A. Belfiore, The IGF system in thyroid cancer: new concepts. Mol. Pathol. 54, 121–124 (2001)
B. Tode, M. Serio, C.M. Rotella, G. Galli, F. Franceschelli, A. Tanini, R. Toccafondi, Insulin-like growth factor-I: autocrine secretion by human thyroid follicular cells in primary culture. J. Clin. Endocrinol. Metab. 69, 639–647 (1989)
V. Vella, G. Pandini, L. Sciacca, R. Mineo, R. Vigneri, V. Pezzino, A. Belfiore, A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J. Clin. Endocrinol. Metab. 87, 245–254 (2002)
R. Malaguarnera, F. Frasca, A. Garozzo, F. Gianì, G. Pandini, V. Vella, R. Vigneri, A. Belfiore, Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. J. Clin. Endocrinol. Metab. 96, 766–774 (2011)
A. Belfiore, R. Malaguarnera, Insulin receptor and cancer. Endocr. Relat. Cancer 18, R125–R147 (2011)
S. Cinti, G. Mitchell, G. Barbatelli, I. Murano, E. Ceresi, E. Faloia, S. Wang, M. Fortier, A.S. Greenberg, M.S. Obin, Adipocyte death defines macrophage localization and functionin adipose tissue of obese mice and humans. J. Lipid Res. 46, 2347–2355 (2005)
R. Cancello, C. Henegar, N. Viguerie, S. Taleb, C. Poitou, C. Rouault, M. Coupaye, V. Pelloux, D. Hugol, J.L. Bouillot, A. Bouloumie, G. Barbatelli, S. Cinti, P.A. Svensson, G.S. Barsh, J.D. Zucker, A. Basdevant, D. Langin, K. Clement, Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidlyobese subjects after surgery-induced weight loss. Diabetes 54, 2277–2286 (2005)
L.K. Bachrach, F.R. Liu, G.N. Burrow, M.C. Eggo, Characterization of insulin-like growth factor-binding proteins from sheep thyroid cells. Endocrinology 125, 2831–2838 (1989)
V. Poulaki, C.S. Mitsiades, C. McMullan, D. Sykoutri, G. Fanourakis, V. Kotoula, S. Tseleni-Balafouta, D.A. Koutras, N. Mitsiades, Regulation of vascular endothelial growth factor expression by onsulin-like growth factor I in thyroid carcinomas. J. Clin. Endocrinol. Metab. 88, 5392–5398 (2003)
A. Belfiore, G. Pandini, V. Vella, S. Squatrito, R. Vigneri, Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer. Biochimie 81, 403–407 (1999)
R. Malaguarnera, A. Morcavallo, A. Belfiore, The Insulin and IGF-I pathway in endocrine glands carcinogenesis. J. Oncol. 2012, 635614 (2012)
C.S. Fox, M.J. Pencina, R.B. D’Agostino, J.M. Murabito, E.W. Seely, E.N. Pearce, R.S. Vasan, Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. Arch. Intern. Med. 168, 587–592 (2008)
E. Fiore, P. Vitti, P. Serum, TSH and risk of papillary thyroid cancer in nodular thyroid disease. J. Clin. Endocrinol. Metab. 97, 1134–1145 (2012)
D.S. McLeod, D.S. Cooper, P.W. Ladenson, K.B. Ain, J.D. Brierley, H.G. Fein, B.R. Haugen, J. Jonklaas, J. Magner, D.S. Ross, M.S.M.C. Skarulis, D.L. Steward, H.R. Maxon, Sherman For The National Thyroid Cancer Treatment Cooperative Study Group SI. Prognosis of differentiated thyroid cancer in relation to serum TSH and thyroglobulin antibody status at time of diagnosis. Thyroid 24, 35–42 (2014)
M. Rivas, P. Santisteban, TSH-activated signaling pathways in thyroid tumorigenesis. Mol. Cell. Endocrinol. 213, 31–45 (2003)
K. Takada, N. Amino, H. Tada, K. Miyai, Relationship between proliferation and cell cycle-dependent Ca2+ influx induced by a combination of thyrotropin and insulin-like growth factor-I in rat thyroid cells. J. Clin. Invest. 86, 1548–1555 (1990)
A. Ciampolillo, C. De Tullio, F. Giorgino, The IGF-I/IGF-I receptor pathway: implications in the pathophysiology of thyroid cancer. Curr. Med. Chem. 12, 2881–2891 (2005)
G. Milazzo, G.L. La Rosa, R. Catalfamo, R. Vigneri, A. Belfiore, Effect of TSH in human thyroid cells: evidence for both mitogenic and antimitogenic effects. J. Cell. Biochem. 49, 231–238 (1992)
B.F.A.M. van der Laan, J.L. Freeman, S.L. Asa, Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues. Thyroid 5, 67–73 (1995)
J. Rezzónico, M. Rezzónico, E. Pusiol, F. Pitoia, H. Niepomiszcze, Metformin treatment for small benign thyroid nodules in patients with insuline resistance. Metab. Syndr. Relat. Disord. 9, 69–75 (2011)
L. Wartofsky, Highlights of the American Thyroid Association Guidelines for patients with thyroid nodules or differentiated thyroid carcinoma: the 2009 revision. Thyroid 19, 1139–1143 (2009)
S. Benvenga, Emerging therapies in sight for the fight against dedifferentiated thyroid cancer. J. Clin. Endocrinol. Metab. 96, 347–350 (2011)
J. Klubo-Gwiezdzinska, J. Costello, A. Patel, A. Bauer, K. Jensen, M. Mete, K.D. Burman, L. Wartofsky, V. Vasko, Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. J. Clin. Endocrinol. Metab. 98, 3269–3279 (2013)
G. Chen, S. Xu, K. Renko, M. Derwahl, Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J. Clin. Endocrinol. Metab. 97, E510–E520 (2012)
Author information
Authors and Affiliations
Corresponding author
Additional information
Hugo Niepomniszcze—in memoriam.
Rights and permissions
About this article
Cite this article
Pitoia, F., Abelleira, E., Bueno, F. et al. Insulin resistance is another factor that increases the risk of recurrence in patients with thyroid cancer. Endocrine 48, 894–901 (2015). https://doi.org/10.1007/s12020-014-0416-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-014-0416-6